Journal article
P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma
Sagar Lonial, Jesus G Berdeja, Meletios-Athanasios Dimopoulos, Sundar Jagannath, Stefan Knop, Hang Quach, Paula Rodríguez-Otero, Paul G Richardson, April Sorrell, Min Chen, Elisabeth Kueenburg, Tuong Vi Nguyen, Kevin Hong, Teresa Peluso, Niels WCJ van de Donk
Clinical Lymphoma Myeloma and Leukemia | Elsevier BV | Published : 2021
Abstract
Background Despite recent advances, new therapies are needed to deepen and extend remissions in early-line relapsed/refractory multiple myeloma (RRMM). Iberdomide (IBER) is a novel, potent oral cereblon E3 ligase modulator (CELMoD®) compound with enhanced tumoricidal and immune-stimulatory effects when compared with IMiD® agents. Preclinically, IBER overcomes IMiD resistance and has synergy with dexamethasone (DEX), daratumumab (DARA), and bortezomib (BORT). In a phase 1/2 trial in patients (pts) with RRMM, IberDd showed efficacy with favorable tolerability, and pharmacodynamic data demonstrated increased NK and T cell proliferation (Lonial S, et al. HemaSphere 2021; 5(S2):49). The EXCALIBER..
View full abstract